Biotechnology start-up Ginkgo Bioworks said on Wednesday that it had raised a $350 million fund to more easily invest in spinout ventures that use its bio-engineering technology in a variety of industries that are just starting to use cutting edge biology.
Biotechnology start-up Ginkgo Bioworks said on Wednesday that it had raised a US$350 million fund to more easily invest in spinout ventures that use its bio-engineering technology in a variety of industries that are just starting to use cutting edge biology.
Proceeds will be used to finance the clinical trials and commercialization of its CAR-T technologies. The post Shenzhen Venture Capital leads $28m Series B round in China's Hrain Biotech appeared first on DealStreetAsia.
Shenzhen Capital Group Leads $28M Series B Round In Biotech Hrain Biotechnology - China Money Network
Shanghai-based oncotherapy-focused firm Hrain biotechnology Co., Ltd. announces on Monday that it raises RMB200 million (US$28 million) in a series B funding round led by venture capital firm Shenzhen Capital Group (SCG). Biomedicine-focused venture capital firm Yangming Kangyi, Xiamen-based investment firm Junchenda Capital, and Shenzhen-based investment firm ChiNext Qianhai Capital also participate in the round. [...] Shenzhen Capital Group Leads $28M Series B Round In Biotech Hrain Biotechnology comes originally from China Money Network. All Rights Reserved.
Seattle-based A-Alpha Bio, a biotechnology startup, has raised $2.8 million in funding. OS Fund led the round with participation from other investors that included AME Cloud Ventures, Boom Capital, Madrona Venture [...]
The current round, led by CMBI, saw the participation of both new and existing investors. The post China's gene-editing startup Qihan Biotech raises $25.5m in Series A+ round appeared first on DealStreetAsia.
Getting money for a biotech startup can be a daunting task. Venture capital is not the only -- and not always the best -- option to fund a life sciences company.
Biotech companies are beginning to resemble traditional tech companies and build products like them. Investment models traditionally applied to early-stage tech startups can now be applied to this "new biotech."
For private (and now public) healthcare and biotech companies, 2018 was a great year to raise capital with 16 companies reaching unicorn status. So far, in 2019, three more companies have been added to the list. Health Catalyst, which went public in July, Lyell Therapeutics and Rakuten Medical all reached the $1 billion valuation mark. Some significant changes happened in 2019, with Auris Health getting bought by Johnson & Johnson for $3.4 billion in February 2019, marking the company's valuation at over $5 billion.
STERLING, Va., August 22, 2019-- Aperiomics, the fast-growing biotech company combining the latest advancements in science, technology, and medicine to change the way healthcare providers identify causes of infection, announced today that they have closed a successful Series A funding round totaling $1.8 million. South Carolina-based investment group VentureSouth leads a group of investors that also includes Pipeline Angels, Propel(x) and a number of high net worth individuals.